The Influence of BRCA1/BRCA2 Mutations on Toxicity Related to Chemotherapy and Radiotherapy in Early Breast Cancer Patients
Authors:
- Magdalena BudrykMBMagdalena Budryk
- Zofia KołoszaZKZofia Kołosza
- Elżbieta NowaraENElżbieta Nowara
- 1 November 2013
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 85 (5) , 278-282
Abstract
Objective: The presence of BRCA gene mutation and low expressions of BRCA proteins are associated with a greater sensitivity of tumor cells to ionizing radiation and to cytostatics damaging the DNA of the cells. The purpose of this study was to estimate the rate of adverse events in BRCA1/2-associated breast cancer patients receiving anthracycline-based chemotherapy compared to patients without mutation. The authors also compared radiotherapy toxicity in these 2 groups. Methods: The analysis included 270 early-stage breast cancer patients treated between 2006 and 2012. All patients were examined for the presence of BRCA1/2 mutations. Results:BRCA mutation was detected in 41 (15%) patients. Toxicity grade 3, especially nausea and vomiting, was observed more often in noncarriers (7 vs. 13%, p = 0.0008). Neutropenia was detected more frequently in patients with BRCA1/2 mutation (32 vs. 10%), but only after 1 cycle of chemotherapy (p = 0.0007). There was increased radiation toxicity in BRCA1/2 patients who underwent mastectomy and neoadjuvant chemotherapy (p = 0.016). Conclusions:BRCA1/2 mutation carriers seemed to be more at risk of neutropenia after the first cycle of the treatment. In terms of other side effects, there was a lack of increased toxicity in this group. Mastectomy and neoadjuvant chemotherapy were risk factors for radiation toxicity in mutation carriers.Keywords
This publication has 15 references indexed in Scilit:
- Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancerBreast Cancer Research, 2012
- Should the Presence of Germline BRCA1/2 Mutations Influence Treatment Selection in Breast Cancer?Journal of Clinical Oncology, 2011
- Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United KingdomClinical Cancer Research, 2006
- BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and PrognosisFamilial Cancer, 2006
- The Role of BRCA1 in the Cellular Response to ChemotherapyJNCI: Journal of the National Cancer Institute, 2004
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiationOncogene, 2003
- A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer: Table 1Journal of Medical Genetics, 2002
- Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 MutationsJournal of Clinical Oncology, 2000
- Paclitaxel-induced cell deathCancer, 2000